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ABSTRACT 
Up to very recently, no treatments had proved effective in progressive multiple 
sclerosis (MS). In 2016, four drugs, two tested in phase 3 and two in phase 2 trials, 
showed a beneficial effect in primary or secondary progressive MS. Although this 
could indicate a turning point in progressive MS treatment, most of these successes 
have been modest and mainly restricted to patients with active inflammation, in the 
context of trials with powerful anti-inflammatory agents. In April 2017, an 
International Panel of experts in MS met to discuss the reasons behind the recent 
successes and past failures in progressive MS trials. This paper summarises these 
reasons, particularly focusing on the main lessons learned for the design of future 
trials. First, drugs’ mechanism of action should tackle the specific pathogenic 
mechanisms that characterise progressive MS. Secondly, trial populations where 
new drugs are to be tested should be carefully chosen, possibly including younger 
patients with shorter disease durations, which have greater chances of showing 
active deterioration during the trial, therefore increasing the power to detect 
treatment effects. Thirdly, outcome measures used in future phase 2 and phase 3 
trials should be highly sensitive and be accompanied by smart trial designs. 
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INTRODUCTION  
Up to very recently, no treatments had proved effective in progressive MS (PMS). In 
2016, though, four drugs, two tested in phase 3 trials1, 2 and two in phase 2 trials3, 4 
showed a beneficial effect in PPMS or SPMS. This change in direction has prompted 
the revision of the reasons underlying recent chain of successes and past failures.  
In this paper, we aim to focus on those reasons behind past failures and 
recent successes. First, we will focus on the drugs tested in past PMS trials, most of 
them not specifically designed to tackle the pathogenic mechanisms that 
characterise the PMS phenotype. Second, we will discuss the type of patient 
included in PMS trials, which has probably had an enormous influence over the 
observed results. Finally, we will mention some methodological issues of these trials, 
mainly related to outcome measures and trial designs, that could have played a role 
in past failures as well as in recent achievements. 
 
DRUGS IN PROGRESSIVE MS TRIALS 
Many of the drugs that have been tested in PMS trials were not initially designed to 
tackle the specific pathogenic mechanisms that characterise the PMS phenotype. 
Instead, they tended to be the same as those tested in RRMS trials (Tables 1 and 
2). This could be justified by the fact that all pathological traits in MS are thought to 
coexist throughout the disease, as part of a continuum, being the differences 
between stages or phenotypes more quantitative than qualitative5, 6. However, these 
differences, even if relatively small, may have played a part in the negative results 
found so far in PMS trials. In addition, the rationale for some of the phase 3 trials 
carried out in PMS was provided by the results of phase 2 studies performed in 
RRMS7-9 (not in PMS) or by the post-hoc subgroup analyses of PMS trials which had 
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overall had negative results10-12. Therefore, the non-optimal choice of the drug might 
have been aggravated by the performance of large phase 3 trials without a previous 
phase 2 trial in progressive MS with the same drug, which could have helped to save 
time and economic resources.  
However, not all drugs tested in PMS have failed to show a beneficial effect in 
delaying disability progression. In 1998, the European Study Group on interferon 
beta (IFN)-1b in SPMS published the results of the first phase 3 trial in SPMS9 (i.e. 
the EUSPMS trial), and these were positive for the primary endpoint (Table 1). 
Additionally, mitoxantrone, a powerful anti-inflammatory treatment, also showed a 
beneficial effect in a phase 3 trial with SPMS patients, published in 200213. 
Unfortunately, though, despite these initially promising results, the use of IFNb or 
mitoxantrone in PMS has been progressively reduced in the clinic, for different 
reasons. With regard to IFNb, the initial positive results could not be confirmed by 
the rest of the phase 3 trials also carried out with IFNb in SPMS14-16 or PPMS17, 18. 
This was attributed to EUSPMS trial population being younger and with higher 
inflammatory activity, i.e. more similar to the RRMS phenotype, than other trial 
populations19. This implied a loss of confidence in the use of IFNb for SPMS, for 
which it had been approved in some countries, especially in those patients without 
any clear evidence of acute macroscopic inflammation, visible with T2-weighted MRI 
sequences. In relation to mitoxantrone, it is its poor safety profile20 that has limited its 
use, which is nowadays almost anecdotal in western countries.  
In 2014, the scenario of treatments for MS started to change when the results 
of the phase 2 MS-STAT trial, which evaluated the efficacy of high doses of 
simvastatin versus placebo in SPMS, were published4. Simvastatin showed an ability 
to reduce the rate of brain volume loss, the primary outcome, and to delay the 
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progression of disability4, 21. Remarkably, unlike the IFNb and the mitoxantrone trials, 
the choice of the drug in the MS-STAT trial was based on a careful evaluation of its 
possible neuroprotective effects22.  
 In 2016, the results of the phase 3 ORATORIO trial were published1, meaning 
the major breakthrough in PMS treatment. The ORATORIO trial showed a clear 
superiority of ocrelizumab, an anti-CD20 monoclonal antibody, as compared to 
placebo, in delaying the accrual of disability in patients with PPMS. Remarkably, it 
was the first time that a drug showed efficacy in PPMS1. In this case, although no 
evidence from any phase 2 trials of ocrelizumab in PMS was available before the 
start of the trial, several studies had already shown a potential role of CD20 B-cells 
in the pathogenesis of progressive MS23-25. B-cells accumulate in the subarachnoid 
space of patients with PMS, in the so-called meningeal follicles23-25, and this 
constituted the main rationale for the ORATORIO trial. Additionally, a post-hoc 
subgroup analysis of the OLYMPUS trial (published in 2009) had shown some 
beneficial effect of rituximab, another anti-CD20 monoclonal antibody similar to 
ocrelizumab, in younger PPMS patients with inflammatory activity26. So, although the 
OLYMPUS trial had been deemed overall negative, the results of this subgroup 
analysis also contributed to the rationale for the use of ocrelizumab in the 
ORATORIO trial.  
The biotin trial for PMS, also published in 2016, showed as well significant 
results in the primary endpoint3. As happened in the ORATORIO trial, the rationale 
for the use of biotin was not its efficacy in RRMS, but its unique mechanism of 
action: biotin activates carboxylases which enhance either the synthesis of fatty 
acids, therefore supporting myelin repair, or the energy production in neurons, 
therefore protecting against hypoxia-driven axonal degeneration27.  
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Finally, the phase 3 EXPAND trial of siponimod in SPMS, presented at 
ECTRIMS 2016, has also shown a beneficial effect versus placebo2, contributing to 
the list of recent trials successful in PMS. Here, although the drug had proved 
effective in a phase 2 RRMS trial (BOLD study) and had a clear anti-inflammatory 
effect28, it also seemed to have neuroprotective effects within the CNS after crossing 
the blood-brain barrier29. This latter characteristic constituted the main rationale for 
its use in SPMS4. 
 Thus, it seems that with all these recent successes, a new era of PMS trials 
might have started. However, a few considerations need to be made. First, 
unfortunately, a careful selection of the drug has not always meant obtaining 
significant results. A clear example is the phase 3 INFORMS trial with fingolimod, a 
drug with a similar profile to that of siponimod, which failed to show efficacy in 
PPMS8. Second, since most of the successful drugs in PMS also had a clear direct 
anti-inflammatory effect, it could be argued that this was in fact the main responsible 
for their success, rather than their neuroprotective effect. In fact, even in those trials 
with positive results, the benefits have been modest and have been predominantly 
restricted to patients with active inflammation, indicating that effective therapies 
positively impacting the pathophysiology of later stages of progressive MS are still 
elusive. Therefore, more research into the pathogenic mechanisms of PMS and the 
mechanisms of action of the potential drugs for PMS is still needed.  
 
TRIAL POPULATIONS  
The choice of the trial population is crucial to be able to capture treatment effects, 
should they exist. There are at least two potential causes of an eventual unfortunate 
choice of trial population: first, the lack of an appropriate definition of progressive 
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MS; second, the ignoring of patients’ disease severity when defining the inclusion 
criteria.  
In relation to the definition problem, in 1996, Lublin and Reingold published 
the first definitions of MS phenotypes30. These could be homogeneously used across 
the scientific community and meant a significant improvement in trial design30. 
However, the lack of precision of the definitions of SPMS and PPMS, which could 
not easily incorporate the presence of clinical or MRI activity, prompted the 
publication of the new definitions of the progressive forms of MS, in 20146. These 
allowed us to use MS disease modifiers to specify whether the patient had 
clinical/MRI inflammatory activity or active progression, on top of the diagnosis of 
SPMS or PPMS, which could be very useful for future trial selection.    
The problem related to ignoring patients’ severity in the inclusion criteria has 
started to be tackled more recently. A trial population with slower disease 
progression than that considered when estimating the required sample size may not 
be powered to detect differences between groups, should they exist. For instance, 
when in 2007 the phase 3 PROMISE trial was published31, one of the reasons 
attributed to its negative results was the low progression rate in the placebo arm, 
which was not predicted when designing the trial. A strategy used to avoid 
unexpected low rates of progression of disability has been the inclusion of patients 
with greater chances of having an active disease over the course of the trial. This 
was the strategy of the ORATORIO trial1. In this study, one of the inclusion criteria 
was to have a relatively short disease duration, especially if the patient was not too 
disabled. This ensured that only patients with steeper accrual of disability were 
included. However, high progression rates have also been seen in negative studies, 
such as the INFORMS trial, where the proportion of patients with progression in the 
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placebo arm was 70%8. This suggests that other factors apart from the presence of 
high progression rates may have also been involved in the success of the 
ORATORIO trial. In fact, in the ORATORIO trial, an additional inclusion criteria was 
that patients had to be 55 years old or younger, whereas previous studies had 
allowed the inclusion of patients with ages up to 6531. So, this younger trial 
population ensured the participation of patients with greater inflammatory activity1, 
more likely to respond to anti-inflammatory treatment regimes. Of note, although the 
ORATORIO trial did not show any statistical differences between subgroups defined 
by inflammatory activity, this was attributed to the lack of power1. Thus, it may be 
possible that the success in the ORATORIO trial was more strongly related to the 
presence of a population with a more inflammatory phenotype1, possibly as a 
consequence of choosing younger participants, than to the presence of high 
progression rates, although both may have contributed.  
 In general, these trials where the study populations are carefully selected to 
increase their power are considered ‘enriched’ trials. Importantly, despite the 
advantages of enriched trials, they may also entail some drawbacks, such as 
questioning the generalisability of the results to all PMS patients, with and without 
the trial population features. An alternative to enriched trials may be the performance 
of subgroup analyses within the trial population to assess whether the efficacy of a 
drug is similar in different subpopulations. Subgroup analyses are generally 
performed if previously defined in the trial protocol. In that case, the trial is usually 
adequately powered for that. Nevertheless, if there is a scientific rationale, it is not 
inappropriate to conduct a subgroup analysis that was not previously defined in the 
trial protocol. Thus, it may be reasonable to approach these post-hoc analyses as 
exploratory and recognise their limited power. 
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OUTCOME MEASURES AND TRIAL DESIGNS  
Phase 3 trials in PMS have clinical measures as primary endpoints. Among these, 
the EDSS-related measures are the most widely used (see Tables 1 and 2). 
However, the EDSS has limitations32-34, which may well have been responsible for 
the lack of significant results in PMS trials.  
Over the years, phase 3 trials in progressive MS have tried different strategies 
to overcome the limitations of the EDSS. One of these was to substitute the EDSS 
by another clinical score with a greater sensitivity to clinical progression, such as the 
Multiple Sclerosis Functional Composite (MSFC) score33, which reflects better than 
the EDSS the upper limb and cognitive functions. For instance, the IMPACT study, 
which in 2002 showed a beneficial effect of IFNb-1a in SPMS when compared to 
placebo, had used the changes in MSFC scores during the trial as primary endpoint. 
Another strategy to overcome the limitations of the EDSS has consisted of using 
composite outcomes of clinical progression instead of a single score. For example 
the MIMS (mitoxantrone, SPMS)13, the CUPID (dronabinol, SPMS)35, the ASCEND 
(natalizumab, SPMS)36 and the INFORMS (fingolimod, PPMS)8 trials used 
composite measures of clinical progression, always involving the EDSS. 
Nevertheless, despite the use of composite primary endpoints, only the MIMS 
study13 of all these was significant. Also following this strategy, in the ORATORIO 
study, the composite NEP (no evidence of progression) was used as an exploratory 
secondary endpoint1, emulating the commonly used NECA (no evidence of clinical 
activity) and NEDA (no evidence of disease activity) for RRMS trials37-40. In the 
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ORATORIO study, significant treatment effects were not only seen in the primary 
endpoint, but also in the NEP endpoint: the proportion of patients without 
progression in the EDSS, NHPT and TWT (all three) was higher among those 
receiving ocrelizumab than in the placebo arm1. A final strategy has resided in 
changing completely the focus of the outcome measure from clinical progression to 
clinical improvement. Although ‘percentage of patients with clinical improvement’ had 
been already used as secondary endpoint in a few RRMS trials such as the phase 3 
Copolymer-141 and CARE-MS II39, it was used as primary endpoint for the first time 
in the biotin trial for progressive MS3 (Table 1). Of note, although the use of 
improvement of disability (instead of delayed progression) as trial primary endpoint is 
still debatable, it is possible that it reflects a genuine aspect of some drugs for 
progressive MS. This would be especially true for drugs with a neuroprotective or 
restorative mechanism of action, as was the case for biotin3, 27, 42.  
Phase 2 trial endpoints mainly consist of non-clinical outcome measures. In 
progressive MS, the most widely used is the brain atrophy rate, which in the MS-
STAT trial was the responsible for the differences between treatment groups in 
favour of simvastatin21. On the other hand, its responsiveness is still limited and 
great efforts are being made to develop new phase 2 outcome measures able to 
detect treatment effects in 6-12 months, instead of the conventional 24 months 
(Tables 1 and 2)43, 44. Along these lines, the recently completed SPRINT-MS trial, 
apart from aiming at the comparison of ibudilast versus placebo to delay the 
disability accumulation in SPMS and PPMS, aimed at head-to-head comparisons of 
several imaging measures in terms of their ability to reflect treatment effects45.    
Regarding the trial design, the vast majority of the PMS trials –and of the MS 
trials in general– so far have used the classic 1:1 scheme, where one active arm is 
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compared to one placebo arm. And in those few trials with two active arms 
compared to one placebo arm13, 16, 17, 46, the two active arms tested two doses of the 
same drug, rather than two active components (Tables 1 and 2). Recent evidence 
from Oncology trials suggests that this trial design could be improved by comparing 
several active drugs to the placebo arm47. Following this innovative multi-arm trial 
suggestion, the phase 2 MS-SMART study was born. It aimed to compare three 
active drugs, fluoxetine, amiloride and riluzole, to placebo, in a proof-of-concept 
drug-repurposing four-arm placebo-controlled trial, which finished the recruitment in 
June 2016 and is currently ongoing48.  
 
CONCLUSIONS 
The recent chain of successes in SPMS and PPMS trials has brought some light to 
the bleak prospect we used to have in relation to treatment options for PMS. So far, 
one of these newly tested drugs, the ocrelizumab, has already been approved for 
patients with PPMS49 and it is likely that more drugs are approved in the near future. 
Thus, this set of fortunate concatenated events might be meaning a turning point in 
the history of trials for PMS, enabling us to assess the reasons behind past failures 
and latest achievements. On the other hand, most of these successes have been 
modest, mainly restricted to patients with active inflammation and in the context of 
trials with powerful anti-inflammatory agents. Thus, although inflammation in 
progressive MS exists and the presence of meningeal follicles is a well-known 
pathogenic mechanism, there are other processes beyond inflammation that have 
not been successfully addressed by many of the drugs recently tested. Therefore, it 
is not surprising that a number of significant failures have also occurred over the 
previous years, despite a careful choice of the tested drug.  
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In sum, it has become clearer that drugs’ mechanism of action must tackle the 
specific pathogenic mechanisms that characterise progressive MS in order to 
increase the chances of success. Also, the trial populations where new drugs are to 
be tested should be carefully chosen. Younger populations with shorter disease 
durations and more rapid progression rates have greater chances of showing active 
deterioration during the years of the trial, therefore increasing the power to detect 
treatment effects, should these exist. Finally, outcome measures in both phase 2 and 
phase 3 trials should be as sensitive as possible to detect treatment effects within a 
short time frame, and be accompanied by a smart trial design able to maximise the 
potential of the trial to find effective drugs in a quick and efficient manner. 
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Table 1. Main trials in SPMS 
 
Drug tested 
(vs. 
placebo) 
Trial 
Condition 
(no. of 
patients 
randomised) 
Duration 
Primary 
endpoint(s) 
Results 
on the 
primary 
endpoint 
Reference 
IFN beta-1b 
SC 8 million 
IU eod 
Phase 3 
(EUSPMS 
study)1 
SPMS 
(n=718) 
Early 
termination 
due to 
obvious 
superiority 
of IFN 
(initially 
planned: 
39 months) 
Time to 3-
month CDP 
on the 
EDSS2 
Positive European 
Study Group 
on IFN beta-
1b in SPMS, 
Lancet 1998, 
phase 3 
IFN beta-1a 
SC 22µg or 
44µg thrice 
weekly 
Phase 3 
(SPECTRIMS 
study)1 
SPMS 
(n=618) 
36 months Time to 3-
month CDP 
on the 
EDSS2 
Negative Li et al. 
(SPECTRIMS 
Study 
Group), 
Neurology 
2001 
IFNb-1b SC 
250µg or 
160µg/m2 of 
body surface 
area eod 
Phase 3 
(NASPMS 
study)1 
SPMS 
(n=939) 
Early 
termination 
for futility 
(initially 
planned: 
36 months) 
Time to 6-
month CDP 
on the 
EDSS2 
Negative Panitch et al. 
(North 
American 
Study Group 
on IFN beta-
1b in SPMS), 
Neurology 
2004 
IFN beta-1a 
IM 
60mcg/week  
 Phase 3 
(IMPACT 
study)1 
SPMS 
(n=436) 
24 months Change in 
the MSFC 
from 
baseline to 
24 months 
Positive Cohen et al., 
Neurology 
2002 
IFN beta-1a 
SC 
22mcg/week 
 Phase 3 (The 
Nordic SPMS 
study)1 
SPMS 
(n=371) 
36 months Time to 6-
month CDP 
on the 
EDSS2 
Negative Andersen et 
al., JNNP 
2004 
Mitoxantrone 
IV 12 mg/m2 
or 5 mg/m2 
of body 
surface 
area/3 
months  
Phase 3 
(MIMS study) 
SPMS or 
PRMS 
course 
(n=188) 
24 months Multivariate 
analysis of 
five clinical 
measures:  
-EDSS 
changes 
(baseline-
final); 
-AI changes 
(baseline-
final); 
-No. of 
treated 
relapses; 
-Time to first 
treated 
relapse; 
-Change in 
standardised 
neurological 
status; 
Positive  Hartung et 
al., Lancet 
2002 
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IVIG 
1g/Kg/month 
Phase 3 
(ESIMS 
study)3 
SPMS 
(n=318) 
24 months Time to 3-
month CDP 
on the 
EDSS2 
Negative Hommes et 
al., Lancet 
2004 
MBP8298 IV 
500mg/6 
months 
Phase 2  SPMS (n=32) 24 months Change in 
the EDSS 
from 
baseline to 
24 months 
Negative4 Warren et al., 
Eur J Neurol 
2006 
MBP8298 IV 
500mg/6 
months 
Phase 3 
(MAESTRO 
study)5 
SPMS 
(n=612) 
24 months Time to 6-
month CDP 
on the 
EDSS2 
Negative Freedman et 
al., Neurology 
2011 
Lamotrigine 
PO 
400mg/day 
 
Phase 2 SPMS 
(n=120) 
24 months Rate of 
change of 
partial 
(central) 
cerebral 
volume over 
24 months 
Negative Kapoor et al., 
Lancet 
Neurol 2010 
Dronabinol 
PO (max. 
dose: 
28mg/day, 
titrated 
against 
bodyweight 
Phase 
unspecified 
(CUPID 
study) 
SPMS 
(n=302), 
PPMS 
(n=191) 
36 months -Time to 6-
month CDP 
on the 
EDSS2  
-Change in 
the MSIS-29-
PHYS from 
baseline to 
36 months 
Negative Zajicek et al., 
Lancet 
Neurol 2013 
Simvastatin 
PO 
80mg/day 
Phase 2 SPMS 
(n=140) 
24 months Annualised 
rate of 
whole-brain 
atrophy  
Positive Chataway et 
al., Lancet 
2014 
Natalizumab 
IV 300mg/4 
weeks 
Phase 3 
(ASCEND 
study) 
SPMS 
(n=887) 
24 months Composite 
outcome: 6-
month CDP 
on EDSS2, or 
TWT 
(≥20%), or 
NHPT 
(≥20%) 
Negative Steiner et al., 
AAN 2016 
Biotin PO 
100mg/8h 
Phase 2 Progressive 
MS: SPMS 
(n=99) or 
PPMS (n=55) 
12 months Proportion of 
patients 
with 
improvement 
of MS-
related 
disability6 at 
month 
9, confirmed 
at month 12 
Positive Tourbah et 
al., MSJ 2016 
Siponimod 
PO 2mg/day 
Phase 3 
(EXPAND 
study) 
SPMS 
(n=1105) 
37 months Time to 3-
month CDP 
on the 
EDSS2 
Positive Kappos L et 
al. ECTRIMS 
2016 
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1: The rationale for the phase 3 trials with IFNb in SPMS was provided by the results of trials carried 
out in RRMS; 2: The definition of EDSS progression depends on the baseline EDSS score; 3: The 
rationale for the ESIMS trial was provided by the results of uncontrolled studies and placebo-
controlled trials in RRMS; 4: Although the results for the main analysis were negative, in the subgroup 
of 20 patients with HLA haplotypes DR2 and/or DR4, MBP8298 treatment had a significant effect on 
the primary endpoint; 5: The rationale for the MAESTRO study was provided by the results of the 
subgroup analysis with HLA haplotypes DR2 and/or DR4; 6: Improvement was defined as: decrease 
of ≥0.5 point or ≥1 point in EDSS (if baseline score was 6–7 or 4.5–5.5, respectively) or a ≥20% 
decrease in timed walk test (TWT) time, compared with the best EDSS or TWT value recorded at 
either the screening or the randomisation visit.  
Abbreviations: AI: ambulation index; EDSS: expanded disability status scale; CDP: confirmed 
disability progression; IFNb-1a/1b: interferon beta 1a/1b; IV: intravenous; MSFC: multiple sclerosis 
functional composite; MSIS-29-PHYS: physical impact subscale of the 29-item multiple sclerosis 
impact scale; NHPT: nine-hole peg test; PO: per oral; PPMS: primary progressive multiple sclerosis; 
PRMS: progressive-relapsing MS; RRMS: relapsing-remitting MS; SC: subcutaneous; SPMS: 
secondary progressive MS; TWT: timed walk test;  
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Table 2. Main trials in PPMS 
 
Drug tested 
(vs. 
placebo) 
Trial 
Condition 
(no. of 
patients 
randomised) 
Duration 
Primary 
endpoint 
Results 
on the 
primary 
endpoint 
Reference 
GA SC 
15mg/12h 
Phase 2 Chronic 
progressive 
MS (n=106); 
out of these, 
31 had PPMS 
(n=23) or 
‘transitional 
progressive 
MS’ (n=8) 
24 months Time to 
confirmed 
progression 
on the 
EDSS1 
 
Negative2 Bornstein 
et al., 
Neurology 
1991 
GA SC 
20mg/day 
Phase 3 
(PROMiSe 
study) 
PPMS 
(n=943) 
Early 
termination 
for futility 
(initially 
planned: 
36 
months) 
Time to 3-
month CDP 
on the 
EDSS1 
Negative Wolinsky 
et al., Ann 
Neurol 
2007 
IFNb-1a IM 
30µg or 
60µg weekly 
Phase 2 PPMS (n=50) 24 months Time to 3-
month CDP 
on the 
EDSS1 
Negative  Leary et 
al., 
Neurology 
2003 
IFNb-1b SC 
8 MIU eod 
Phase 2 PPMS and 
‘transitional 
progressive 
MS’ (n=73) 
24 months Time to 3-
month CDP 
on the 
EDSS1 
Negative  Montalban 
et al., MSJ 
2009 
Rituximab 
IV 
1000mg/24 
weeks 
Phase 2/3 
(OLYMPUS 
study) 
PPMS 
(n=439) 
96 weeks Time to 3-
month CDP 
on the 
EDSS1 
Negative3 Hawker et 
al., Ann 
Neurol 
2009 
Fingolimod 
PO 
0.5mg/day 
Phase 3 
(INFORMS 
study)4 
PPMS 
(n=970) 
36 months Composite 
endpoint: 
Time to 3-
month CDP 
on either 
EDSS, or 
TWT, or 
NHPT  
Negative Lublin et 
al., Lancet 
2016 
Ocrelizumab 
IV 600mg 
(300mg x2) 
/24 weeks 
 Phase 3 
(ORATORIO 
study)5 
PPMS 
(n=732) 
120 weeks Percentage 
of patients 
with 3-
month CDP 
on the 
EDSS1,6 
Positive Montalban 
et al., N 
Engl J 
Med. 2016 
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Table 2 (footnote).  
1: The definition of EDSS progression depends on the baseline EDSS score; 2: In the subset of 31 
patients with either PPMS or transitional progressive MS, some hint of efficacy was observed; this 
motivated the phase 3 trial; 3: In the subgroup of 72 patients with age <51 years and presence of 
gadolinium-enhancing lesions in the MRI, rituximab significantly delayed progression of disability (vs. 
placebo); 4: The rationale for the INFORMS trial was provided by in-vitro and in-vivo studies that 
suggested that fingolimod could inhibit neurodegeneration. No phase 2 trial was performed with 
fingolimod in PPMS; 5: The rationale for the ORATORIO trial was provided by the results of the 
subgroup analysis of the OLYMPUS trial (in younger patients with inflammatory activity). No phase 2 
trial was performed with ocrelizumab in PPMS; 6: Although the primary endpoint was the percentage 
of patients with CDP, this percentage was obtained through a time-to-event analysis.   
Abbreviations: EDSS: expanded disability status scale; CDP: confirmed disability progression; IFNb-
1a/1b: interferon beta 1a/1b; IV: intravenous; NHPT: nine-hole peg test; PO: per oral; PPMS: primary 
progressive multiple sclerosis.  
 
 
 
 
